Search

Anthrax immune globulin human

It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue

Propidium

Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes

Caprylic alcohol

Caprylic alcohol has been used in trials studying the treatment of Essential Tremor.

Forasartan

As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.

RAV12

RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. … RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid.

Octamoxin

This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

CHGN111

Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

Dimethyl sulfone

Zidesamtinib

[L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … another ROS1 inhibitor has failed rather than as an alternative first choice.

INNO-305

INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.